In ovarian tumors, XCR1 was expressed in the majority (~80%) of BDCA3+ cDC1s (Figures 1C, D), suggesting enrichment of XCR1+ cDC1s in tumors and possibly, an enrichment of a more mature cDC1 DC population since Clec9a and BDCA3 are reported to also be expressed in pre-DCs, while XCR1 was not (28). The gene discussed is CLEC9A; the disease is ovarian neoplasm.